Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Nov;8(21):1338.
doi: 10.21037/atm-20-3216.

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial

Claudia De Angelis  1 , Michail Ignatiadis  1 , Martine Piccart-Gebhart  1   2
Affiliations
Editorial

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial

Claudia De Angelis et al. Ann Transl Med. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-3216). MI declares: Consultant or advisory role: Celgene, Novartis, Pfizer, Seattle Genetics, Tesaro; Speaker honoraria: Novartis; Travel grants: Pfizer, Amgen; Research grants to my Institute: Roche, Menarini Silicon Biosystems, Janssen Diagnostics, Pfizer; MPG declares: Board member (scientific board): Oncolytics; Consultant (honoraria): AstraZeneca, Camel-IDS, Crescendo Biologics, Debiopharm, G1 Therapeutics, Genentech, Huya, Immunomedics, Lilly, Menarini, MSD, Novartis, Odonate, Periphagen, Pfizer, Roche, Seattle Genetics; Research grants to my Institute: AstraZeneca, Lilly, MSD, Novartis, Pfizer, Radius, Roche-Genentech, Servier, Synthon. The other author has no other conflicts of interest to declare.

Comment on

References

    1. Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009;27:1160-7. 10.1200/JCO.2008.18.1370 - DOI - PMC - PubMed
    1. Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019;381:307-16. 10.1056/NEJMoa1903765 - DOI - PubMed
    1. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2020;382:514-24. 10.1056/NEJMoa1911149 - DOI - PubMed
    1. Sledge GW, Jr, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2019;6:116-24. 10.1001/jamaoncol.2019.4782 - DOI - PMC - PubMed
    1. Turner NC, Ro J, André F, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015;373:209-19. 10.1056/NEJMoa1505270 - DOI - PubMed